TY - JOUR
T1 - Association between use of oral hypoglycemic agents in Japanese patients with type 2 diabetes mellitus and risk of depression
T2 - A retrospective cohort study
AU - Akimoto, Hayato
AU - Tezuka, Kotoe
AU - Nishida, Yayoi
AU - Nakayama, Tomohiro
AU - Takahashi, Yasuo
AU - Asai, Satoshi
N1 - Publisher Copyright:
© 2019 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Type 2 diabetes mellitus (T2DM) is a risk factor for depression. Since brain insulin resistance plays a potential role in depression, the future risk of depression in patients with T2DM may be altered depending on the class of oral hypoglycemic agent (OHA) used for T2DM therapy. The aim of the present study was to determine if specific classes of OHAs are associated with a risk for comorbid depression in T2DM. Japanese adult patients with T2DM (n = 40 214) were divided into a case group (with depression; n = 1979) and control group (without depression; n = 38 235). After adjustment for age [adjusted odds ratio (AOR) for 10 years: 1.03; 95% confidence interval (CI): 0.99-1.07; P =.1211], sex [AOR for female: 1.39; 95% CI: 1.26-1.53; P <.0001], hemoglobin A1c [AOR for 1.0%: 1.18; 95% CI: 1.11-1.26; P <.0001], duration of T2DM [AOR for 1 year: 1.00; 95% CI: 0.99-1.01; P =.4089], and history of seven medical conditions, the odds ratios for the development of depression was significantly lower for dipeptidyl peptidase-4 (DPP-4) inhibitors [AOR: 0.31; 95% CI: 0.24-0.42; P <.0001]. However, there was no significant association for the other classes of OHAs. Therefore, this study finds that there is less risk of depression associated with the use of DPP-4 inhibitors for the treatment of T2DM.
AB - Type 2 diabetes mellitus (T2DM) is a risk factor for depression. Since brain insulin resistance plays a potential role in depression, the future risk of depression in patients with T2DM may be altered depending on the class of oral hypoglycemic agent (OHA) used for T2DM therapy. The aim of the present study was to determine if specific classes of OHAs are associated with a risk for comorbid depression in T2DM. Japanese adult patients with T2DM (n = 40 214) were divided into a case group (with depression; n = 1979) and control group (without depression; n = 38 235). After adjustment for age [adjusted odds ratio (AOR) for 10 years: 1.03; 95% confidence interval (CI): 0.99-1.07; P =.1211], sex [AOR for female: 1.39; 95% CI: 1.26-1.53; P <.0001], hemoglobin A1c [AOR for 1.0%: 1.18; 95% CI: 1.11-1.26; P <.0001], duration of T2DM [AOR for 1 year: 1.00; 95% CI: 0.99-1.01; P =.4089], and history of seven medical conditions, the odds ratios for the development of depression was significantly lower for dipeptidyl peptidase-4 (DPP-4) inhibitors [AOR: 0.31; 95% CI: 0.24-0.42; P <.0001]. However, there was no significant association for the other classes of OHAs. Therefore, this study finds that there is less risk of depression associated with the use of DPP-4 inhibitors for the treatment of T2DM.
KW - depression
KW - dipeptidyl peptidase-4 inhibitor
KW - oral hypoglycemic agent
KW - type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=85075571555&partnerID=8YFLogxK
U2 - 10.1002/prp2.536
DO - 10.1002/prp2.536
M3 - Article
C2 - 31768258
AN - SCOPUS:85075571555
SN - 2052-1707
VL - 7
JO - Pharmacology Research and Perspectives
JF - Pharmacology Research and Perspectives
IS - 6
M1 - e00536
ER -
